Novavax, Inc. (NVAX) — closed signal from March 2, 2026
Partial Published before the outcome was known, scored automatically when the window closed on May 31, 2026.
Predicted vs. what happened
What happened
Reached 46% of the predicted growth at its peak, without hitting the target.
The thesis — published March 2, 2026
Novavax surprised the market with a profitable quarter and much higher sales, which changed how people view its ability to execute. A licensing deal with Pfizer and new recurring royalty income make the story less about a single day pop and more about ongoing revenue. The stock is still very volatile, so the safer approach is to buy small amounts on dips rather than chase big jumps.
Primary drivers
- Unexpected profitable quarter and big sales beat boost turnaround view
- Pfizer licensing deal adds recurring royalty and milestone revenue
- Analyst upgrades may lift fair-value expectations further
- Price swings let you buy in stages on pullbacks
How it played out
NVAX: thesis rose but did not reach the target
Lyra published NVAX on 2026-03-02 at $10.20 with expected growth of 30% and a target of $13.25. The thesis pointed to an unexpected profitable quarter, a big sales beat, a Pfizer licensing deal with recurring royalty and milestone revenue, possible analyst upgrades, and volatility that could allow staged buying on pullbacks.
Inside the window from 2026-03-02 to 2026-05-31, NVAX peaked at $11.61 on 2026-05-27, up 13.8%. It stayed below the $13.25 target and never reached it. The stock ended at $10.97. The thesis partly played out, because the price rose, but the target was missed.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.